- Alpha Tau’s IMPACT trial is expected to enroll up to 30 patients across the U.S., Canada, and Israel, focusing on patients with newly diagnosed, inoperable pancreatic adenocarcinoma.
- The ReSTART study is to evaluate Alpha DaRT in patients with recurrent cutaneous squamous cell carcinoma, a common form of skin cancer.
- Patient enrollment for both trials is expected to be completed by the end of the first quarter of 2026.
Alpha Tau Medical (DRTS) drew strong retail attention on Monday as the oncology therapeutics firm approaches a key catalyst, with markets awaiting crucial patient enrolment data in pancreatic cancer and cutaneous squamous cell carcinoma (cSCC) trials.
DRTS shares were down 4% in pre-market trading at the time of writing.
IMPACT Study For Pancreatic Cancer
Alpha Tau’s IMPACT trial is expected to enroll up to 30 patients across the U.S., Canada, and Israel, focusing on those with newly diagnosed, inoperable pancreatic adenocarcinoma. Patient enrollment is expected to be completed by the end of the first quarter of 2026.
Participants will continue standard chemotherapy while receiving the company’s Alpha DaRT, a targeted radiation therapy delivered directly into tumors using ultrasound-guided endoscopy.
The study aims to evaluate the safety, feasibility, and effectiveness of the treatment, while also tracking tumor response and survival outcomes. Researchers will additionally assess whether some patients with locally advanced disease become eligible for surgery after treatment, a key potential benefit of the therapy, the company said.
ReSTART Trial Targets Skin Cancer Opportunity
Alpha Tau is currently running its multi-center ReSTART study to evaluate Alpha DaRT in patients with recurrent cutaneous squamous cell carcinoma (cSCC), a common form of skin cancer. Patient enrollment is expected to be completed in the first quarter of 2026.
The trial supports the use of Alpha DaRT, particularly for patients who are not eligible for surgery or standard radiation.
The company has already secured Breakthrough Device Designation from the U.S. Food and Drug Administration for this indication, as well as for recurrent glioblastoma multiforme, a type of brain tumor, and oral cavity cancers.
This designation reflects the regulator’s view that the therapy could offer significant advantages over existing treatments and allows for an accelerated review and development pathway. It is also part of the FDA’s Total Product Life Cycle Advisory Program.
DRTS Stock: Retail Sentiment Signals High Expectations
Retail sentiment on Stocktwits remained in the ‘bullish’ zone over the past 24 hours, accompanied by ‘high’ message volumes.
Chatter was largely bullish, with one user stating that the company’s current market value could look very low in hindsight if there are further positive updates from the ReSTART trial.
Another user said the stock’s current value feels like a “massive mispricing.”
Year-to-date, the stock has gained nearly 38%.
For updates and corrections, email newsroom[at]stocktwits[dot]com.